China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its ACYW135 meningococcal polysaccharide conjugate vaccine. The vaccine is designed to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis of groups A, C, Y, and W135.
Vaccine Profile
Epidemic cerebrospinal meningitis is an acute infectious disease caused by Neisseria meningitidis, characterized by acute onset, rapid progression, strong infectivity, high latent infection rates, and high mortality. The ACYW135 meningococcal polysaccharide conjugate vaccine, an upgrade based on clinically approved groups A and C meningococcal polysaccharide conjugate vaccines, is designed to elicit a memory immune response in the body. It can be used to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis of groups A, C, Y, and W135.
Related Developments
In a related development, CanSino Biologics (HKG: 6185) received approval in China in December last year for its MCV4 (trade name: ManHaiXing), an ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier). This approval highlights the growing interest in developing vaccines to address the significant public health challenges posed by meningococcal infections.-Fineline Info & Tech
